Share Price and Basic Stock Data
Last Updated: October 28, 2025, 2:30 pm
| PEG Ratio | 2.07 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Marksans Pharma Ltd, a prominent player in the pharmaceutical industry, reported a share price of ₹180 and a market capitalization of ₹8,166 Cr. The company recorded a steady increase in sales, rising from ₹1,491 Cr in March 2022 to ₹1,852 Cr in March 2023, and further to ₹2,177 Cr in March 2024. For the trailing twelve months (TTM), revenue stood at ₹2,652 Cr, indicating strong momentum in the business. Quarterly sales also showcased a positive trajectory, with the latest reported figure for September 2023 at ₹531 Cr, up from ₹486 Cr in March 2023. The increase in sales can be attributed to effective operational strategies and a growing demand for pharmaceutical products, aligned with the industry’s overall growth trend. This robust revenue performance positions Marksans Pharma well within the competitive landscape, reflecting its resilience and adaptability in a rapidly evolving market.
Profitability and Efficiency Metrics
Marksans Pharma demonstrated commendable profitability metrics, with a net profit of ₹383 Cr for the fiscal year ending March 2025, a rise from ₹265 Cr in March 2023. The operating profit margin (OPM) stood at 20% for the year, reflecting effective cost management in operations. The company also reported a return on equity (ROE) of 16.8% and a return on capital employed (ROCE) of 20%, both of which are competitive against typical industry benchmarks. Furthermore, the interest coverage ratio (ICR) of 51.37x indicates a strong ability to meet interest obligations, showcasing financial health. However, the cash conversion cycle (CCC) of 247 days raises concerns regarding operational efficiency, indicating potential delays in inventory turnover and receivables collection. The firm’s ability to enhance operational efficiency while maintaining profitability will be crucial for sustaining growth.
Balance Sheet Strength and Financial Ratios
Marksans Pharma’s balance sheet exhibits strength, with total assets reported at ₹3,240 Cr and liabilities at ₹3,240 Cr, reflecting a solid asset base. The company’s equity capital remained stable at ₹45 Cr, while reserves increased to ₹2,422 Cr, demonstrating a strong retention of earnings. Borrowings stood at ₹322 Cr, resulting in a low debt-to-equity ratio of 0.01, which is significantly below industry norms, suggesting a conservative financial structure. The company’s price-to-book value (P/BV) ratio of 4.08x indicates that the market values its equity significantly higher than its book value, reflecting investor confidence. Additionally, the current ratio of 4.62x illustrates excellent liquidity, ensuring that the company can meet its short-term obligations comfortably. This financial stability provides a strong foundation for future growth and strategic initiatives.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Marksans Pharma reveals a diversified ownership structure. Promoters hold 43.87% of the company, while foreign institutional investors (FIIs) own 19.89%, and domestic institutional investors (DIIs) account for 5.50%. The public holds 30.74%, indicating a healthy distribution of shares. The increase in FII holdings from 14.90% in June 2023 to 19.89% reflects growing investor confidence in the company’s prospects. Moreover, the number of shareholders reached 2,56,221, showcasing broad retail interest. However, the declining promoter shareholding from 48.60% in September 2022 to the current level may raise concerns about long-term commitment. Overall, the diverse investor base coupled with increasing institutional interest suggests a positive outlook for Marksans Pharma’s stock performance.
Outlook, Risks, and Final Insight
Looking ahead, Marksans Pharma’s robust revenue growth and strong profitability metrics position it favorably in the pharmaceutical sector. However, risks such as the high cash conversion cycle and declining promoter stake could pose challenges. The company must focus on improving operational efficiency and addressing investor concerns regarding promoter commitment. Enhancing inventory turnover and receivables management will be essential to mitigate risks associated with prolonged cash cycles. On the other hand, continued expansion in product offerings and market penetration could support sustained growth. Should the company successfully address these operational challenges while leveraging its financial strengths, it may enhance shareholder value significantly in the long term. Overall, Marksans Pharma stands at a crucial juncture with opportunities balanced against inherent risks, necessitating strategic focus and execution.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Marksans Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,766.58 Cr | 1,179.77 | 50.40 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 434 | 453 | 480 | 486 | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 |
| Expenses | 361 | 372 | 403 | 376 | 398 | 417 | 453 | 450 | 462 | 506 | 543 | 582 | 520 |
| Operating Profit | 73 | 80 | 77 | 110 | 102 | 114 | 133 | 110 | 128 | 136 | 139 | 127 | 100 |
| OPM % | 17% | 18% | 16% | 23% | 20% | 21% | 23% | 20% | 22% | 21% | 20% | 18% | 16% |
| Other Income | 16 | 14 | 18 | 11 | 10 | 19 | 5 | 17 | 15 | 11 | 28 | 15 | 6 |
| Interest | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 |
| Depreciation | 11 | 14 | 13 | 14 | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 |
| Profit before tax | 76 | 78 | 79 | 104 | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 |
| Tax % | 21% | 23% | 21% | 21% | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% |
| Net Profit | 60 | 60 | 62 | 83 | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 |
| EPS in Rs | 1.46 | 1.51 | 1.57 | 1.81 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 |
Last Updated: August 20, 2025, 7:10 am
Below is a detailed analysis of the quarterly data for Marksans Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 620.00 Cr.. The value appears to be declining and may need further review. It has decreased from 708.00 Cr. (Mar 2025) to 620.00 Cr., marking a decrease of 88.00 Cr..
- For Expenses, as of Jun 2025, the value is 520.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 582.00 Cr. (Mar 2025) to 520.00 Cr., marking a decrease of 62.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 100.00 Cr.. The value appears to be declining and may need further review. It has decreased from 127.00 Cr. (Mar 2025) to 100.00 Cr., marking a decrease of 27.00 Cr..
- For OPM %, as of Jun 2025, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 16.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 77.00 Cr., marking a decrease of 39.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 24.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 33.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.29. The value appears to be declining and may need further review. It has decreased from 2.00 (Mar 2025) to 1.29, marking a decrease of 0.71.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:52 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,652 |
| Expenses | 512 | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,094 | 2,151 |
| Operating Profit | 118 | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 529 | 502 |
| OPM % | 19% | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 20% | 19% |
| Other Income | 4 | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 70 | 60 |
| Interest | 19 | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 15 |
| Depreciation | 16 | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 86 |
| Profit before tax | 86 | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 461 |
| Tax % | 15% | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | 21% | 26% | 24% | |
| Net Profit | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 352 |
| EPS in Rs | 1.87 | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 7.73 |
| Dividend Payout % | 5% | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% | 9% | 9% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 51.35% | -25.89% | -86.75% | 227.27% | 122.22% | 51.25% | 97.52% | -21.76% | 41.71% | 18.87% | 21.59% |
| Change in YoY Net Profit Growth (%) | 0.00% | -77.24% | -60.85% | 314.02% | -105.05% | -70.97% | 46.27% | -119.28% | 63.47% | -22.84% | 2.72% |
Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 21% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | 27% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 30% |
| 3 Years: | 48% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 17% |
| Last Year: | 17% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 2:47 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 |
| Reserves | 90 | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 |
| Borrowings | 173 | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 |
| Other Liabilities | 188 | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 |
| Total Liabilities | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 |
| Fixed Assets | 146 | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 |
| Other Assets | 344 | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 |
| Total Assets | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 |
Below is a detailed analysis of the balance sheet data for Marksans Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,020.00 Cr. (Mar 2024) to 2,422.00 Cr., marking an increase of 402.00 Cr..
- For Borrowings, as of Mar 2025, the value is 322.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 244.00 Cr. (Mar 2024) to 322.00 Cr., marking an increase of 78.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 372.00 Cr. (Mar 2024) to 451.00 Cr., marking an increase of 79.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,240.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,681.00 Cr. (Mar 2024) to 3,240.00 Cr., marking an increase of 559.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 982.00 Cr.. The value appears strong and on an upward trend. It has increased from 776.00 Cr. (Mar 2024) to 982.00 Cr., marking an increase of 206.00 Cr..
- For CWIP, as of Mar 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2024) to 27.00 Cr., marking an increase of 18.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 26.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,230.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,869.00 Cr. (Mar 2024) to 2,230.00 Cr., marking an increase of 361.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,240.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,681.00 Cr. (Mar 2024) to 3,240.00 Cr., marking an increase of 559.00 Cr..
Notably, the Reserves (2,422.00 Cr.) exceed the Borrowings (322.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -55.00 | 84.00 | 36.00 | -65.00 | -40.00 | 32.00 | 162.00 | 306.00 | 148.00 | 217.00 | 215.00 | 207.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 98 | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 | 75 |
| Inventory Days | 102 | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 | 270 |
| Days Payable | 83 | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 | 98 |
| Cash Conversion Cycle | 118 | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 | 247 |
| Working Capital Days | -13 | 17 | 59 | 77 | 70 | 97 | 87 | 104 | 121 | 122 | 129 | 142 |
| ROCE % | 37% | 44% | 23% | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 12,641,259 | 1.88 | 210.29 | 12,641,259 | 2025-04-22 17:25:27 | 0% |
| UTI Aggressive Hybrid Fund | 2,078,253 | 0.46 | 21.94 | 2,078,253 | 2025-04-22 17:25:27 | 0% |
| UTI Large & Mid Cap Fund | 1,082,611 | 0.58 | 11.43 | 1,082,611 | 2025-04-22 17:25:27 | 0% |
| UTI Retirement Fund | 1,049,499 | 0.28 | 11.08 | 1,049,499 | 2025-04-22 17:25:27 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 225,777 | 0.66 | 3.76 | 225,777 | 2025-04-22 17:25:27 | 0% |
| UTI Healthcare Fund | 232,711 | 0.32 | 2.46 | 232,711 | 2025-04-22 17:25:27 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 2,691 | 0.49 | 0.04 | 2,691 | 2025-04-22 17:25:27 | 0% |
| Groww Nifty Total Market Index Fund | 557 | 0.02 | 0.01 | 557 | 2025-04-22 17:25:27 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Diluted EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Cash EPS (Rs.) | 10.28 | 8.59 | 7.00 | 5.66 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Revenue From Operations / Share (Rs.) | 57.88 | 48.05 | 40.87 | 36.42 | 33.62 |
| PBDIT / Share (Rs.) | 13.22 | 11.23 | 8.80 | 7.35 | 8.46 |
| PBIT / Share (Rs.) | 11.38 | 9.59 | 7.65 | 6.25 | 7.58 |
| PBT / Share (Rs.) | 11.12 | 9.35 | 7.45 | 6.05 | 7.38 |
| Net Profit / Share (Rs.) | 8.44 | 6.95 | 5.85 | 4.56 | 5.83 |
| NP After MI And SOA / Share (Rs.) | 8.40 | 6.92 | 5.88 | 4.56 | 5.83 |
| PBDIT Margin (%) | 22.83 | 23.37 | 21.52 | 20.17 | 25.16 |
| PBIT Margin (%) | 19.65 | 19.96 | 18.72 | 17.16 | 22.53 |
| PBT Margin (%) | 19.21 | 19.45 | 18.23 | 16.60 | 21.95 |
| Net Profit Margin (%) | 14.58 | 14.46 | 14.32 | 12.53 | 17.33 |
| NP After MI And SOA Margin (%) | 14.51 | 14.40 | 14.37 | 12.53 | 17.33 |
| Return on Networth / Equity (%) | 15.42 | 15.19 | 15.25 | 15.53 | 26.90 |
| Return on Capital Employeed (%) | 18.66 | 18.97 | 18.75 | 19.93 | 33.35 |
| Return On Assets (%) | 11.74 | 11.70 | 12.15 | 11.39 | 19.42 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 |
| Asset Turnover Ratio (%) | 0.88 | 0.89 | 0.96 | 1.04 | 0.73 |
| Current Ratio (X) | 4.62 | 4.78 | 4.91 | 3.37 | 3.02 |
| Quick Ratio (X) | 2.85 | 3.19 | 3.49 | 2.18 | 1.67 |
| Inventory Turnover Ratio (X) | 3.58 | 1.21 | 1.35 | 1.30 | 1.74 |
| Dividend Payout Ratio (NP) (%) | 7.14 | 7.22 | 3.81 | 5.47 | 1.71 |
| Dividend Payout Ratio (CP) (%) | 5.86 | 5.84 | 3.19 | 4.41 | 1.49 |
| Earning Retention Ratio (%) | 92.86 | 92.78 | 96.19 | 94.53 | 98.29 |
| Cash Earning Retention Ratio (%) | 94.14 | 94.16 | 96.81 | 95.59 | 98.51 |
| Interest Coverage Ratio (X) | 51.37 | 45.43 | 43.67 | 35.61 | 43.36 |
| Interest Coverage Ratio (Post Tax) (X) | 33.81 | 29.11 | 30.07 | 23.12 | 30.87 |
| Enterprise Value (Cr.) | 9417.36 | 6244.01 | 2540.86 | 1577.14 | 1869.83 |
| EV / Net Operating Revenue (X) | 3.59 | 2.87 | 1.37 | 1.06 | 1.36 |
| EV / EBITDA (X) | 15.72 | 12.27 | 6.37 | 5.24 | 5.40 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| Retention Ratios (%) | 92.85 | 92.77 | 96.18 | 94.52 | 98.28 |
| Price / BV (X) | 4.08 | 3.33 | 1.83 | 1.55 | 2.31 |
| Price / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.10 | 0.11 |
After reviewing the key financial ratios for Marksans Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.28. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 10.28, marking an increase of 1.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 57.88. It has increased from 48.05 (Mar 24) to 57.88, marking an increase of 9.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 11.23 (Mar 24) to 13.22, marking an increase of 1.99.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.38. This value is within the healthy range. It has increased from 9.59 (Mar 24) to 11.38, marking an increase of 1.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.12. This value is within the healthy range. It has increased from 9.35 (Mar 24) to 11.12, marking an increase of 1.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has increased from 6.95 (Mar 24) to 8.44, marking an increase of 1.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 22.83. This value is within the healthy range. It has decreased from 23.37 (Mar 24) to 22.83, marking a decrease of 0.54.
- For PBIT Margin (%), as of Mar 25, the value is 19.65. This value is within the healthy range. It has decreased from 19.96 (Mar 24) to 19.65, marking a decrease of 0.31.
- For PBT Margin (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has decreased from 19.45 (Mar 24) to 19.21, marking a decrease of 0.24.
- For Net Profit Margin (%), as of Mar 25, the value is 14.58. This value exceeds the healthy maximum of 10. It has increased from 14.46 (Mar 24) to 14.58, marking an increase of 0.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 14.40 (Mar 24) to 14.51, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 15.19 (Mar 24) to 15.42, marking an increase of 0.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.66. This value is within the healthy range. It has decreased from 18.97 (Mar 24) to 18.66, marking a decrease of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 11.74. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 11.74, marking an increase of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has decreased from 0.89 (Mar 24) to 0.88, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 4.62. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.62, marking a decrease of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 3.19 (Mar 24) to 2.85, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 1.21 (Mar 24) to 3.58, marking an increase of 2.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.14. This value is below the healthy minimum of 20. It has decreased from 7.22 (Mar 24) to 7.14, marking a decrease of 0.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 20. It has increased from 5.84 (Mar 24) to 5.86, marking an increase of 0.02.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.86. This value exceeds the healthy maximum of 70. It has increased from 92.78 (Mar 24) to 92.86, marking an increase of 0.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.14. This value exceeds the healthy maximum of 70. It has decreased from 94.16 (Mar 24) to 94.14, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 51.37. This value is within the healthy range. It has increased from 45.43 (Mar 24) to 51.37, marking an increase of 5.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 33.81. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 33.81, marking an increase of 4.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9,417.36. It has increased from 6,244.01 (Mar 24) to 9,417.36, marking an increase of 3,173.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has increased from 2.87 (Mar 24) to 3.59, marking an increase of 0.72.
- For EV / EBITDA (X), as of Mar 25, the value is 15.72. This value exceeds the healthy maximum of 15. It has increased from 12.27 (Mar 24) to 15.72, marking an increase of 3.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 92.85. This value exceeds the healthy maximum of 70. It has increased from 92.77 (Mar 24) to 92.85, marking an increase of 0.08.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.33 (Mar 24) to 4.08, marking an increase of 0.75.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
- Net Profit Margin: 14.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.66% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.42% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 33.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.6 (Industry average Stock P/E: 50.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053 | companysecretary@marksanspharma.com http://www.marksanspharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Srinivas Mishra | Independent Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mrs. Shailaja Vardhan | Independent Director |
FAQ
What is the intrinsic value of Marksans Pharma Ltd?
Marksans Pharma Ltd's intrinsic value (as of 28 October 2025) is 173.32 which is 5.29% lower the current market price of 183.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 8,275 Cr. market cap, FY2025-2026 high/low of 359/162, reserves of ₹2,422 Cr, and liabilities of 3,240 Cr.
What is the Market Cap of Marksans Pharma Ltd?
The Market Cap of Marksans Pharma Ltd is 8,275 Cr..
What is the current Stock Price of Marksans Pharma Ltd as on 28 October 2025?
The current stock price of Marksans Pharma Ltd as on 28 October 2025 is 183.
What is the High / Low of Marksans Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Marksans Pharma Ltd stocks is 359/162.
What is the Stock P/E of Marksans Pharma Ltd?
The Stock P/E of Marksans Pharma Ltd is 23.6.
What is the Book Value of Marksans Pharma Ltd?
The Book Value of Marksans Pharma Ltd is 54.4.
What is the Dividend Yield of Marksans Pharma Ltd?
The Dividend Yield of Marksans Pharma Ltd is 0.45 %.
What is the ROCE of Marksans Pharma Ltd?
The ROCE of Marksans Pharma Ltd is 20.0 %.
What is the ROE of Marksans Pharma Ltd?
The ROE of Marksans Pharma Ltd is 16.8 %.
What is the Face Value of Marksans Pharma Ltd?
The Face Value of Marksans Pharma Ltd is 1.00.